Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression

Gilead Sciences’ daily pill Biktarvy has been one of biopharma’s great success stories, riding its market leading HIV efficacy data to one of the best launches on record. Now, settling into its role as an established brand, Biktarvy is sporting four-year data that will look to keep patients on board even longer.